Amedisys Inc [AMED] stock prices are up 0.03% to $91.57 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AMED shares have lost -1.12% over the last week, with a monthly amount drifted -1.12%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amedisys Inc [NASDAQ: AMED] stock has seen the most recent analyst activity on July 29, 2024, when Deutsche Bank downgraded its rating to a Hold but kept the price target unchanged to $101 for it. Previously, William Blair downgraded its rating to Mkt Perform on July 01, 2024. On June 07, 2023, downgrade downgraded it’s rating to Hold but maintained its price target of $97 on the stock. Cantor Fitzgerald started tracking the stock assigning a Neutral rating and suggested a price target of $87 on April 21, 2023. Barclays initiated its recommendation with a Equal Weight and recommended $93 as its price target on March 13, 2023. Raymond James downgraded its rating to Mkt Perform for this stock on October 27, 2022. In a note dated August 02, 2022, UBS downgraded an Sell rating on this stock and revised its target price from $145 to $95.
The stock price of Amedisys Inc [AMED] has been fluctuating between $82.15 and $98.95 over the past year. Currently, Wall Street analysts expect the stock to reach $143.38 within the next 12 months. Amedisys Inc [NASDAQ: AMED] shares were valued at $91.57 at the most recent close of the market. An investor can expect a potential return of 56.58% based on the average AMED price forecast.
Analyzing the AMED fundamentals
The Amedisys Inc [NASDAQ:AMED] reported sales of 2.32B for trailing twelve months, representing a surge of 5.65%. Gross Profit Margin for this corporation currently stands at 0.4% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.05%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.12 and Total Capital is 0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 91.14 points at the first support level, and at 90.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 91.99, and for the 2nd resistance point, it is at 92.40.
Ratios To Look Out For
It’s worth pointing out that Amedisys Inc [NASDAQ:AMED]’s Current Ratio is 1.19. In addition, the Quick Ratio stands at 1.19 and the Cash Ratio stands at 0.51. Considering the valuation of this stock, the price to sales ratio is 1.29, the price to book ratio is 2.61 and price to earnings (TTM) ratio is 36.46.
Transactions by insiders
Recent insider trading involved North Michael Paul, Former Officer, that happened on Nov 07 ’24 when 11221.0 shares were purchased.
